Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Dose-Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of R01 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors, Including Squamous Cell Lung Cancer, Gastric Cancer, and Esophageal Cancer

NCT07806500 is registered in ClinicalTrials.gov with Beijing Anjianxi Bio-Medical Technology Co., Ltd. as lead sponsor.

NCT NCT07806500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Dose-Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of R01 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors, Including Squamous Cell Lung Cancer, Gastric Cancer, and Esophageal Cancer
Lead sponsor
Beijing Anjianxi Bio-Medical Technology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer, squamous cell lung cancer